Endoron Medical

    Endoron is developing a catheter-based endograft stapling solution to overcome the challenges associated with the sealing and fixation of endografts used for the minimally invasive repair of abdominal aortic aneurysms.

    The EndoStapling solution, designed to avoid highly invasive, high-mortality open surgery, is meant to secure an endograft's fixation and to improve sealing mechanisms. About 400,000 new patients in the U.S. and Europe are diagnosed with AAA disease every year, with 42% presenting complex anatomies.

    Founded in 2019, Endoron Medical builds on an invention from Prof. Ron Karmeli (Hadassah Hospital, Jerusalem), who is co-founder and Chief Medical Officer of the Company.

    Cécile Dupont, Senior Associate and Program Director at Sofinnova Partners MS Start III Fund, is joining the Endoron management team to bring greater operational and strategic support.

    SofinnovaCapital

    The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

    SofinnovaMD Start

    The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

    SofinnovaCrossover

    The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

    SofinnovaIndustrial Biotech

    Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

    SofinnovaTelethon

    The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

    Welcome to our new website – a fresh look that represents a new SofinnovaFind out more